CDL-Oxford

The Oxford Creative Destruction Lab (CDL) has relaunched its Senior School Girls Programme, following a hiatus owing to the pandemic.

Girls aged 16-18 from Oxfordshire schools have been paired with CDL mentors to observe meetings between the mentors and venture founders at a CDL session.

It is a path down which the most celebrated minds in history have stumbled – even Thomas Edison, inventor of the lightbulb and other household devices, rashly predicted alchemy becoming possible within a century.

Which is why Creative Destruction Lab (CDL) does not deal in crystal balls. Rather the Lab – which was founded in Toronto in 2012 and brought to the School in 2019 – is a non-profit provider of programmes to nurture seed-stage, science- and technology-based companies, enhancing their chances of commercial success through expert-led mentoring initiatives.

CDL-Oxford, part of the global network Creative Destruction Lab, has expanded its number of programme streams this year to include Climate and FinTech.

CDL-Oxford launches CDL FinTech, a new stream that will supercharge financial technology ventures in the United Kingdom and beyond, to spur the next stage of the fintech revolution. The stream will support commercially-driven, seed-stage science and tech-based ventures focused on fintech 2.0 areas like embedded finance, financial access and the future of data science and regulation.

Pamoja Capital recently joined an undisclosed round together with Ocean Azul Partners to accelerate Senecio’s ability to bring its core technologies to market. Pamoja Capital was first introduced to Senecio’s founder, Hanan Lepek, by the Creative Destruction Lab programme in Oxford’s Artificial INtelligence stream last year.

Following the success of the first AI stream, Creative Destruction Lab Oxford (CDL-Oxford) embarks on a new journey pursuing technological innovation applied to healthcare. The new stream aims at facilitating and speeding up the commercialisation of technological advancements in the life sciences domain. The areas of interest include diagnostics, medical devices, therapeutics, and AI driven drug discovery.